Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 10/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.43 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.43 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.43 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.43 |
| ▸ | GJB2 | P29033 | 2/20 | 0.42 |
| ▸ | CDC25B | P30305 | 7/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TACR2 | P21452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5140581 | 0.88 | PTPN1 (0.43) | PTPN1PTPN2PTPN11SSTR1SSTR2 | |
| SCHEMBL5139349 | 0.88 | PTPN1 (0.42) | PTPN1PTPN2PTPN11SSTR1SSTR2 | |
| SCHEMBL5139854 | 0.86 | NT5E (0.45) | PTPN1PTPN2PTPN11SSTR1SSTR2 | |
| SCHEMBL9117871 | 0.85 | SSTR1 (0.53) | PTPN1PTPN2PTPN11SSTR1SSTR2 | |
| SCHEMBL9117860 | 0.85 | SSTR1 (0.53) | PTPN1PTPN2PTPN11SSTR1SSTR2 | |
| SCHEMBL5139933 | 0.82 | NT5E (0.43) | PTPN1PTPN2PTPN11SSTR1SSTR2 | |
| SCHEMBL10262410 | 0.81 | PTPN1 (0.49) | PTPN1PTPN2PTPN11SSTR1SSTR2 | |
| SCHEMBL5140579 | 0.79 | PTPN1 (0.44) | PTPN1PTPN2PTPN11SSTR1SSTR2 | |
| SCHEMBL5140251 | 0.79 | PTPN1 (0.45) | PTPN1PTPN2PTPN11SSTR1SSTR2 | |
| SCHEMBL5139347 | 0.78 | PTPN1 (0.42) | PTPN1PTPN2PTPN11SSTR1SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664372-B2 | Process for producing 1,2-trans-glycoside compound | GLYTECH, INC. (JP) | 2014-03-04 | — | — | US | disclosed |
| US-20120232256-A1 | PROCESS FOR PRODUCING 1,2-TRANS-GLYCOSIDE COMPOUND | OTSUKA CHEMICAL CO., LTD. | 2012-09-13 | — | — | US | disclosed |
| US-8212013-B2 | Phenyl 3,4,6-tri-O-benzyl-2-O-(1,1,2,2-tetramethyl-dimethylene phosphonoyl)- beta -D-thioglucopyranoside; inhibits formation of o-ester by-product resulting from the conventional glycosilation reaction of pyranose compounds of 1,2-trans form, affording 1,2-transglycoside compounds with high selectivity | OTSUKA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20080177049-A1 | Process for Producing 1,2-Trans-Glycoside Compound | GLYTECH, INC. (JP) | 2008-07-24 | — | — | US | disclosed |
| EP-1849794-A1 | PROCESS FOR PRODUCING 1,2-TRANS-GLYCOSIDE COMPOUND | Otsuka Chemical Co., Ltd. (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232256-A1 | PROCESS FOR PRODUCING 1,2-TRANS-GLYCOSIDE COMPOUND | ADH1C, ADH1A, CYP2E1 | PTPN1 2778/4885PTPN2 3058/4885PTPN11 3157/4885 |
| US-20080177049-A1 | Process for Producing 1,2-Trans-Glycoside Compound | ADH1C, ADH1A, CYP2E1 | PTPN1 2778/4885PTPN2 3058/4885PTPN11 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.